Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03604302 · ClinicalTrials.gov registry record · NA
Evaluation of Preoperative Functional Magnetic Resonance Imaging (fMRI) in Patients With Brain Tumors
A NA study of Brain Tumor, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT03604302: Active NA study of Brain Tumor, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03604302 is a NA study of Brain Tumor that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 33 participants, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03604302, a NA study of Brain Tumor, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test the accuracy of using an imaging technique called breath-holding functional magnetic resonance imaging (BH fMRI) in addition to the standard imaging test described above. This study will allow the researchers to find out whether using BH fMRI in combination with the standard approach is the same as, better, or worse than the standard approach used alone.
Primary Outcome
The primary objective is to examine if the false negative results of BOLD fMRI adjacent to brain tumors can be compensated for by measurements of BH-MRI and subsequent calibration of the BOLD response. We will have two sets of data: 1) the data obtained using routine techniques to analyze the BOLD fMRI data; and 2) the data obtained where the BOLD fMRI data was analyzed incorporating BH data. Every data point obtained in 1) will have a corresponding data point using 2), the BH MRI data, to adjus
Conditions Studied
Interventions
- DEVICE fMRI Paradigms
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2018-08-01 |
| Est. Completion | 2026-07 |
| Phase | NA |
What the registry record for NCT03604302 still lists
NCT03604302 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 281-participant average among 69 other Brain Tumor trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which fMRI Paradigms is the first listed.
NCT03604302 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03604302 about?
NCT03604302 is a clinical study titled "Evaluation of Preoperative Functional Magnetic Resonance Imaging (fMRI) in Patients With Brain Tumors". The purpose of this study is to test the accuracy of using an imaging technique called breath-holding functional magnetic resonance imaging (BH fMRI) in addition to the standard imaging test described above. This study will allow the researchers to find out whether using BH fMRI in combination with ...
What is the current status of trial NCT03604302?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 33 participants. The study started on 2018-08-01. Estimated completion is 2026-07.
What conditions does trial NCT03604302 study?
This clinical trial studies the following conditions: Brain Tumor.
What interventions are being tested in trial NCT03604302?
The interventions under investigation include: fMRI Paradigms (DEVICE).
Who is sponsoring clinical trial NCT03604302?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03604302 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03604302's enrollment target sits among peer trials
33 39th of 69 higher than 29 of 69 other Brain Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Cognitive Training in the Virtual Reality Setting With Children Undergoing Radiotherapy for Brain Tumors
RECRUITING · NA
-
Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption
RECRUITING · NA
-
Ommaya Reservoir Placement for Brain Tumor Biomarker Access
RECRUITING · NA
-
Mapping of Human Cognition
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
- NCT05225363 · 33 participants · Phase 1
Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI